Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21908568 | 0.88 | TRPV6 (0.50) | KDM4ELMNARAB9ASMN1; SMN2SPHK2 | |
| SCHEMBL19947782 | 0.88 | TRPV6 (0.50) | KDM4ELMNARAB9ASMN1; SMN2SPHK2 | |
| SCHEMBL19948638 | 0.88 | TRPV6 (0.50) | KDM4ELMNARAB9ASMN1; SMN2SPHK2 | |
| SCHEMBL8806151 | 0.81 | ADRA2A (0.52) | SMN1; SMN2LTA4HHRH3CHRM3 | |
| SCHEMBL22110281 | 0.80 | SLC18A2 (0.43) | LTA4HCHRM3SLC18A2 | |
| SCHEMBL11385902 | 0.80 | RAB9A (0.50) | RAB9ASMN1; SMN2ACHEKMT2A | |
| SCHEMBL10684415 | 0.77 | SLC18A2 (0.61) | SLC18A2KMT2A | |
| SCHEMBL14509642 | 0.76 | LTA4H (0.45) | LTA4HSPHK2SPHK1HRH3 | |
| SCHEMBL12125006 | 0.75 | — | — | |
| SCHEMBL19617897 | 0.75 | TRPV6 (0.55) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190099-A1 | NOVEL PYRIMIDINE DERIVATIVE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION PROCESS THEREOF, AND PHARMACEUTICAL COMPOSITION USING THE SAME | SPARK BIOPHARM, INC. (KR) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190099-A1 | NOVEL PYRIMIDINE DERIVATIVE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION PROCESS THEREOF, AND PHARMACEUTICAL COMPOSITION USING THE SAME | DPYD, NUDT1, NUDT5 | KDM4E 1344/4885LMNA 4437/4885RAB9A 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.